Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)

Circulation. 2021 Jun;143(22):2208-2210. doi: 10.1161/CIRCULATIONAHA.120.053463. Epub 2021 Jun 1.

Jesper Jensen^{1

2}, Massar Omar^{3

4}, Caroline Kistorp^{5

2}, Christian Tuxen⁶, Ida Gustafsson⁶, Lars Køber^{7

2}, Finn Gustafsson^{7

2}, Jens Faber^{8

2}, Julie L Forman⁹, Jacob E Møller^{3

7

10}, Morten Schou^{1

2

10}

¹ Department of Cardiology (J.J., M.S.), Herlev and Gentofte University Hospital, Denmark.
² Department of Clinical Medicine (J.J., C.K., L.K., F.G., J.F., M.S.), University of Copenhagen, Denmark.
³ Department of Cardiology, Odense University Hospital, Denmark (M.O., J.E.M.).
⁴ Steno Diabetes Center Odense, Denmark (M.O.).
⁵ Department of Endocrinology (C.K.), Rigshospitalet, Copenhagen, Denmark.
⁶ Department of Cardiology, Bispebjerg and Frederiksberg University Hospital, Copenhagen, Denmark (C.T., I.G.).
⁷ Department of Cardiology (L.K., F.G., J.E.M.), Rigshospitalet, Copenhagen, Denmark.
⁸ Department of Internal Medicine, Center of Endocrinology and Metabolism (J.F.), Herlev and Gentofte University Hospital, Denmark.
⁹ Section of Biostatistics (J.L.F.), University of Copenhagen, Denmark.
¹⁰ Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark (M.O., J.E.M.).

No abstract available

Keywords: body composition; diabetes mellitus, type 2; empagliflozin; heart failure; insulin resistance; sodium-glucose transporter 2 inhibitors.

Publication types